Sökning: onr:"swepub:oai:DiVA.org:uu-431895" >
Different patterns ...
-
Persson, Frederik
(författare)
Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic) : A multinational observational study.
- Artikel/kapitelEngelska2018
Förlag, utgivningsår, omfång ...
-
2018-08-31
-
Wiley,2018
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-431895
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-431895URI
-
https://doi.org/10.1002/edm2.36DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:230815564URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Aims: The understanding of second-line use of glucose-lowering drugs (GLDs) in the general population with type 2 diabetes (T2D) treatment is important as recent results have shown cardiovascular benefits with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA). Our aim was to describe second-line GLD treatment patterns in four Nordic countries.Methods: All T2D patients treated with GLD between 2006 and 2015 were identified in prescribed drug registries in Denmark, Finland, Norway and Sweden, and linked with National Patient and Cause of Death Registries. Second-line treatment was defined as a prescription of a second GLD class following ≥6 months of metformin monotherapy. Index was the date of first dispense of the second-line drug.Results: A rapid uptake of newer GLDs (GLP-1RA, DPP-4i and SGLT-2i) over the 10-year observation period was seen in Denmark, Finland and Norway, while slower in Sweden. In 2015, 33,880 (3.1%) of 1,078,692 T2D patients initiated second-line treatment, and newer GLDs were more commonly used in Finland (92%), Norway (71%) and Denmark (70%) vs Sweden (44%). In 2015, the use of older GLDs (insulin and sulphonylureas) was 7-fold greater in Sweden compared to Finland (49% vs 7%), and 1.6-fold greater compared with Denmark and Norway (49% vs 30% and 29%, respectively).Conclusions: Despite comparable demography and healthcare systems in four neighbouring countries, surprisingly large differences in second-line use of newer GLDs were found. With recent evidence of potential cardiovascular benefits with newer GLDs, such differences may have an important impact on cardiovascular outcomes.
Ämnesord och genrebeteckningar
-
SGLT2
-
observational study
-
second‐line
-
type 2 diabetes
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Bodegard, Johan
(författare)
-
Lahtela, Jorma T
(författare)
-
Nyström, ThomasKarolinska Institutet
(författare)
-
Jørgensen, Marit E
(författare)
-
Jensen, Majken Linneman
(författare)
-
Gulseth, Hanne L
(författare)
-
Thuresson, Marcus
(författare)
-
Hoti, Fabian
(författare)
-
Nathanson, DavidKarolinska Institutet
(författare)
-
Norhammar, AnnaKarolinska Institutet
(författare)
-
Birkeland, Kåre I
(författare)
-
Eriksson, Johan G
(författare)
-
Eriksson, JanUppsala universitet,Klinisk diabetologi och metabolism(Swepub:uu)janer909
(författare)
-
Karolinska InstitutetKlinisk diabetologi och metabolism
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Endocrinology, diabetes & metabolism: Wiley1:42398-9238
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Persson, Frederi ...
-
Bodegard, Johan
-
Lahtela, Jorma T
-
Nyström, Thomas
-
Jørgensen, Marit ...
-
Jensen, Majken L ...
-
visa fler...
-
Gulseth, Hanne L
-
Thuresson, Marcu ...
-
Hoti, Fabian
-
Nathanson, David
-
Norhammar, Anna
-
Birkeland, Kåre ...
-
Eriksson, Johan ...
-
Eriksson, Jan
-
visa färre...
- Artiklar i publikationen
-
Endocrinology, d ...
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet